Recently, an unbiased, genome-wide synthetic lethal CRISPR screen was performed in breast cancer cells in hypoxia to establish potential vulnerabilities that, together with inhibition of CA9 expression, would enhance cell death and limit therapeutic resistance, offering an avenue toward suppressing tumor resistance and recurrence (Chafe et al., 2021). This evidence concerns the gene CA9 and neoplasm.